CRNX Crinetics Pharmaceuticals (CRNX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001658247
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
154
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $400.0K priced
What the filings say about CRNX
Insiders, 180 days
-$366.1K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-07-30
Crinetics Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Crinetics Pharmaceuticals, Inc. insiders sold a net $366.1K of stock across 141 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Mar 12, 2026.
- The trade is 15.6% of the 19,225 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Vivaldi Coelho Rogerio sold about $120.0K of CRNX on Jul 2, 2026; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 3, 2026.
- The trade is 9.5% of the 6,400 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Okey Stephanie sold about $22.0K of CRNX on Jun 17, 2026; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 3, 2026.
- The trade is 89.8% of the 7,008 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Okey Stephanie sold about $224.1K of CRNX on Jun 17, 2026; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 16, 2026.
- The trade is 80.9% of the 105,289 shares held after it.
- 3 other insiders sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Dev. & Operating Officer Knight Jeff E. sold about $3.4M of CRNX on Apr 8, 2026, the largest insider sale at the company since 2024; 3 other insiders sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 19, 2025.
- The trade is 3.5% of the 112,018 shares held after it.
- 5 other insiders sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Knight Jeff E. sold about $149.6K of CRNX on Mar 16, 2026; 5 other insiders sold within 30 days and 154 funds added in the latest 13F quarter.141 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$366.1K over 180 days
below 53% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
154 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
+640.7% year over year
more than 94% of Pharma & Biotech
Margin
-6046.2% net margin
below 98% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CRNX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+112.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CRNX: institutional holders (13F)
13F holdings, latest reported quarter
15,840,219 sh
$592.7M
9,758,938 sh
$365.2M
8,989,098 sh
$336.4M
7,131,084 sh
$266.8M
6,463,551 sh
$241.9M
Congress trades in CRNX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-07-30 · disclosed 36 days later
$15,001 - $50,000
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Bought 2025-04-17 · disclosed 19 days later
$1,001 - $15,000
Sold 2025-03-19 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-01-29 · disclosed 13 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CRNX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ROGERIO VIVALDI COELHO
Filed 2026-07-02
$232.1K
JEFF KNIGHT
Filed 2026-07-02
$1.8M
CRNX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity SAI Merger Arbitrage Fund
$27.1M position · as of 2026-07-31
4.3%
Virtus Biotech Etf
$3.3M position · as of 2026-07-31
3.3%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$571.6K position · as of 2026-07-31
2.8%
ALPS Medical Breakthroughs ETF
$3.8M position · as of 2026-05-31
2.4%
AMG GW&K Small Cap Growth Fund
$3.5M position · as of 2026-07-31
1.7%
Impax Small Cap Fund
$16.3M position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
6
Phase 2
1 active
4
Phase 3
2 active
3
Multi-phase
2 active
What changed recently
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
2026-10-16 · Recruiting → Active Not Recruiting
Phase 3
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrom
2026-10-15 · Active Not Recruiting → Completed
PHASE1,PHASE2
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Ex
2026-10-14 · Recruiting → Active Not Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.6M
$8.1M
$3.8M
+230%
+25%
2024
$10.5M
$19.1M
$4.2M
+262%
-7%
2023
$5.7M
$13.9M
$2.2M
+152%
-6%
2022
$5.6M
$1.6M
$2.7M
+30%
-10%
2021
$4.1M
$10.3M
$2.5M
+101%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $366.1K sold by insiders over 180 days, 154 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
CRNX financials
Revenue growth
+640.7%
XBRL, annual
Net margin
-6046.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$42.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRNX
| FY Dec 2025 | $7.7M |
| FY Dec 2024 | $1.0M |
| FY Dec 2023 | $4.0M |
| FY Dec 2022 | $4.7M |
| FY Dec 2021 | n/a |
| Jun 2026 | $25.1M |
| Mar 2026 | $10.7M |
| Dec 2025 | $6.2M |
| Sep 2025 | $143.0K |
| Jun 2025 | $1.0M |
| Mar 2025 | $361.0K |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-1,190%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CRNX
| FY Dec 2025 | -6,046% |
| FY Dec 2024 | -28,720% |
| FY Dec 2023 | -5,345% |
| FY Dec 2022 | -3,460% |
| FY Dec 2021 | n/a |
| Jun 2026 | -481.1% |
| Mar 2026 | -1,191% |
| Dec 2025 | -1,993% |
| Sep 2025 | n/a |
| Jun 2025 | -11,216% |
| Mar 2025 | -26,807% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$425.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CRNX
| FY Dec 2025 | -$383.7M |
| FY Dec 2024 | -$234.0M |
| FY Dec 2023 | -$173.3M |
| FY Dec 2022 | -$116.9M |
| FY Dec 2021 | -$89.0M |
| Jun 2026 | -$94.7M |
| Mar 2026 | -$125.5M |
| Dec 2025 | -$93.4M |
| Sep 2025 | -$111.6M |
| Jun 2025 | -$89.1M |
| Mar 2025 | -$89.7M |
| Dec 2024 | -$67.9M |
| Sep 2024 | -$63.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-42.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CRNX
| FY Dec 2025 | -40.2% |
| FY Dec 2024 | -32.0% |
| FY Dec 2023 | -50.1% |
| FY Dec 2022 | -50.6% |
| FY Dec 2021 | -43.0% |
| Jun 2026 | -42.4% |
| Mar 2026 | -39.2% |
| Dec 2025 | -40.2% |
| Sep 2025 | -44.4% |
| Jun 2025 | -36.9% |
| Mar 2025 | -30.8% |
| Dec 2024 | -32.0% |
| Sep 2024 | -40.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-38.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRNX
| FY Dec 2025 | -36.3% |
| FY Dec 2024 | -28.8% |
| FY Dec 2023 | -43.4% |
| FY Dec 2022 | -46.6% |
| FY Dec 2021 | -40.3% |
| Jun 2026 | -38.4% |
| Mar 2026 | -35.9% |
| Dec 2025 | -36.3% |
| Sep 2025 | -39.7% |
| Jun 2025 | -33.2% |
| Mar 2025 | -28.1% |
| Dec 2024 | -28.8% |
| Sep 2024 | -35.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-44.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CRNX
| FY Dec 2025 | -42.8% |
| FY Dec 2024 | -34.5% |
| FY Dec 2023 | -48.6% |
| FY Dec 2022 | -50.9% |
| FY Dec 2021 | -42.4% |
| Jun 2026 | -44.6% |
| Mar 2026 | -41.4% |
| Dec 2025 | -42.8% |
| Sep 2025 | -47.6% |
| Jun 2025 | -40.2% |
| Mar 2025 | -33.8% |
| Dec 2024 | -34.5% |
| Sep 2024 | -41.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.7%
TTM free cash flow over market value at close 2026-09-02
FCF yield CRNX
| FY Dec 2025 | -8.7% |
| FY Dec 2024 | -4.9% |
| FY Dec 2023 | -7.3% |
| FY Dec 2022 | -11.9% |
| FY Dec 2021 | -6.6% |
| Jun 2026 | -10.8% |
| Mar 2026 | -11.0% |
| Dec 2025 | -8.7% |
| Sep 2025 | -9.1% |
| Jun 2025 | -11.5% |
| Mar 2025 | -8.6% |
| Dec 2024 | -4.9% |
| Sep 2024 | -5.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CRNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-09-02. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $7.7M | $1.0M | $4.0M | $4.7M |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M |
| Net income | -$465.3M | -$298.4M | -$214.5M | -$163.9M |
| EPS (diluted) | -4.95 | -3.69 | -3.69 | -3.15 |
| Operating cash flow | -$377.9M | -$230.2M | -$168.6M | -$115.2M |
| Cash | $101.5M | $264.5M | $54.9M | $32.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
CRNX Stock Sonar score 5/7 axes
Find similar shapesCompareCRNX ranks highest on growth (94th percentile) and risk and compliance (58th), and lowest on insider conviction (22nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CRNX filings, in plain words
Are Crinetics Pharmaceuticals insiders buying or selling CRNX?
In the 180 days to 2026-10-28, Crinetics Pharmaceuticals insiders were net sellers, a net $366.1K across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded CRNX?
Yes. In the year to 2026-10-28, 1 House member disclosed buying CRNX and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-07-30.
Read the full summary
In the 180 days to 2026-10-28, Crinetics Pharmaceuticals insiders were net sellers of CRNX, a net $366.1K across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying CRNX and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-07-30. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
